Here are five points:
1. The study will launch this summer and last for three years.
2. In this study, patients will not have the ability to sign up, volunteer or give consent. The drug will be used in dire situations where patients will likely be unconscious, or at the very least, unable to make important decisions.
3. The double blind drug trial called STAAMP is meant to stop profuse bleeding in critical cases where there is a high likelihood of bleeding out.
4. The University of Utah, along with three other major universities, will take part in the three-year study of tranexamic acid, known as TXA, a blood clotting agent. TXA is already used in heart and orthopedic surgeries in hospitals, and has a record of stopping blood loss.
5. AirMed patients suffering from severe trauma with risk of significant bleeding will be administered the IV drug or a saline placebo in flight. Neither the patient nor the emergency responders will know who is getting the treatment.
More articles on quality & infection control:
The value of an apology — 5 points on what patients want after a medical error
Commonwealth Informatics adds Dr. Trevor Gibbs to executive team: 4 notes
Sepsis enters spotlight with Patty Duke’s death: 6 things to know
